Harold J. Wanebo, MD

Emeritus Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Wanebo is Emeritus Professor of Surgery in the surgical oncology section at Roger Williams Medical Center, an affiliate of Chobanian and Avedisian School of Medicine. Dr. Harold Wanebo has spent years training, teaching, and working as a surgical oncologist. He eventually moved into consulting and has delivered over 500 presentations and authored 290 peer reviewed journal articles. His research interests include surgical oncology, hepatobiliary surgery, colorectal surgery and gastrointestinal cancer management and pelvic malignancy surgery. He has been affiliated with numerous professional organizations throughout his academic career including the American College of Surgeons, the American Association for Cancer Research, the New England Surgical Society and many others.

Harold J. Wanebo, MD, FACS, attended the University of Colorado Denver School of Medicine. Following his graduation in 1961, he went on to intern at Cornell University in Ithaca, New York, and serve his surgical residency training at the University of California, San Francisco, and Memorial Sloan Kettering Cancer Center, where he trained in tumor immunology. Dr. Wanebo is a board certified in general surgery with the American Board of Surgery. He is an active member of the American Head and Neck Society, the Society of Surgical Oncology, and the American Society of Clinical Oncology. Dr. Wanebo is an extensively published author and has spent 2 years in the army with 1 year in Vietnam. As a result of his outstanding performance in the field of surgical oncology, The International Association of HealthCare Professionals (IAHCP) has selected Harold J. Wanebo, MD, FACS, to be featured in the premier publication of The Leading Physicians of the World.

Publications

  • Published 10/2/2015

    Stephen AH, Fallon EA, Kalife E, Wanebo H. Radiation-associated sarcoma after recurrent colorectal primary tumor: A complex surgical case. J Surg Oncol. 2015 Nov; 112(6):658-61. PMID: 26430853.

    Read at: PubMed

  • Published 7/9/2014

    Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014 Oct; 25(10):2036-41. PMID: 25009013.

    Read at: PubMed

  • Published 4/3/2014

    Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun 1; 20(11):3023-32. PMID: 24700741.

    Read at: PubMed

  • Published 4/1/2014

    Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 2014 Apr; 37(2):162-6. PMID: 23275269.

    Read at: PubMed

  • Published 4/16/2013

    Best C, Calianese D, Szulak K, Cammarata G, Brum G, Carbone T, Still E, Higgins K, Ji F, DI W, Wanebo H, Wan Y. Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death. Oncol Lett. 2013 Jun; 5(6):1854-1858. PMID: 23833655.

    Read at: PubMed

View All 253 Publications:   View Full Profile in BUMC

Websites

Education

  • University of Colorado Boulder, MD
  • Regis College, BS

View all profiles